An international team of researchers has uncovered a crucial mechanism that allows certain cancer cells to hide from the body’s immune defenses, a discovery that could reshape future cancer treatments. The study, led by scientists at Julius-Maximilians-Universität Würzburg (JMU) in collaboration with partners in the United States, reveals how the powerful cancer-driving protein MYC not only fuels tumor growth but also helps tumors remain undetected by the immune system.

A new epidemiological study reported today finds that consistent heavy alcohol consumption over a lifetime is associated with a significantly increased risk of colorectal cancer, particularly rectal cancer, while reducing or quitting drinking may lower that risk. The findings were published online in the peer-reviewed journal Cancer.

Syngene announced a significant extension of its long-standing collaboration with global biopharmaceutical leader Bristol Myers Squibb (BMS). The renewed strategic agreement will now continue through 2035, marking a new decade of deep partnership aimed at driving drug discovery, development, and commercialization.

Swiss, a third-generation family-owned business, leverages over 25 years of expertise in generic and specialty pharmaceuticals. Our proficiency extends to the development and manufacturing of a diverse range of sterile dosage forms. Operating globally, we export our products under our brand name, reaching over 80 countries.

Hiring Regulatory Affairs